8:45 am Chair’s Opening Remarks
Managing Toxicity, Modulating the Tumour Microenvironment, & Overcoming Resistance in Claudin-Targeted Therapies
9:00 am Workshop: Mitigating Toxicity & Ensuring Safety in Claudin-Targeted Cancer Therapies
Synopsis
This workshop will focus on strategies to mitigate toxicity and enhance safety in Claudin-targeted therapies, addressing common side effects and preclinical profiling. Participants will learn about clinical trial designs and approaches to manage patient safety effectively
10:30 am Evaluating the Role of Claudins in Tumour Microenvironment & Immune Modulation
Synopsis
- Investigating how claudin expression affects the tumor microenvironment, including interactions with stromal cells, immune cells, and extracellular matrix components 11:00 Morning Break 11:15 Networking Rooms Tomoka Nakajima Executive Director, Asset Lead Astellas Pharma US
- Deep dive discussion on the dual role of claudin in promoting immune evasion and facilitating immune cell infiltration, and the implications for immunotherapy
- Uncovering recent advancements in targeting claudin to modulate the tumor microenvironment and enhance the efficacy of cancer immunotherapies
11:00 am Coffee Break
11:15 am Networking Rooms
Delving into Claudin Biology & Translational Success in Claudin-Targeted Therapies
12:00 pm Roundtable Discussion: Insights into Claudin Biology & Its Impact On Cancer Progression
Synopsis
- Understanding the dynamic expression patterns of Claudin 18.2, 6, and 9 in different cancer stages and the implications for therapeutic targeting
- Outlining the role of claudin proteins in tumor microenvironment interactions and how these interactions influence cancer progression and metastasis
- Identifying how understanding claudin biology can inform clinical strategies and improve therapeutic outcomes, including the development of targeted delivery systems and combination therapies
12:45 pm Translational Development: Bridging Preclinical Findings to Clinical Success in Claudin-Targeted Therapies
Synopsis
- Understanding the importance of developing companion diagnostics for Claudintargeted therapies, including the identification and validation of biomarkers to ensure patient selection
- Showcasing strategies to address challenges in translational development, such as achieving target specificity, managing toxicity profiles, and optimizing therapeutic windows
- Analyzing case studies highlighting the successful transition of Claudin-targeted therapies from preclinical stages to clinical trials, with a focus on lessons learned and best practices
1:15 pm Lunch Break & Virtual Networking
Assessing Innovative Therapeutic Approaches & Toxicity Management in Claudin-Targeted Therapies
2:15 pm Claudin 1: in Cancer and Organ Fibrosis
Synopsis
- Examining the role of Claudin 1 in cancer and organ fibrosis
- Discussing the pre-clinical development and the therapeutic potential of monoclonal antibodies and ADCs targeting Claudin 1
- Addressing the phase I development for Claudin 1-targeted therapies
2:45 pm Next-Generation Cell Therapies Targeting Claudin: Overcoming Challenges & Improving Outcomes
Synopsis
- Showcasing the latest advancements in next-generation cell therapies targeting claudin, emphasizing novel approaches beyond CAR-T
- Understanding improvements in toxicity profiles and the durability of therapeutic responses in solid tumours
- Highlighting early clinical data and preclinical insights to illustrate the effectiveness and potential of these innovative therapies
3:15 pm Future Directions in Claudin-Targeted Therapy Development
Synopsis
- Implementing emerging trends and innovations in Claudin-targeted therapies, including next-generation antibody technologies and novel therapeutic modalities
- Understanding the potential of targeting other claudin isoforms, such as Claudin 6, in different cancer types and the associated scientific challenges and opportunities
- Reviewing advancements in preclinical models and technologies that support the development of more effective and safer claudin-targeted therapies, such as organoid models and advanced imaging techniques